Evidence map›Paper›PMID 41347830›Full record

ArticleOncology reports2026

Saikosaponin D overcomes gemcitabine resistance in pancreatic cancer via AKT/mTOR pathway inhibition and synergistic induction of apoptosis and autophagy.

Rui Zheng, Yusi Liu, Sen Zhou, Guimei Liu, Xiaobin Liu, Yiyuan Yang, Yufu Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Rui Zheng *Department of Medical Immunology, Yan'an Medical College, Yan'an University, Yan'an, Shaanxi 716000, P.R. China.
Yusi Liu *Department of Medical Immunology, Yan'an Medical College, Yan'an University, Yan'an, Shaanxi 716000, P.R. China.
Sen ZhouDepartment of Medical Immunology, Yan'an Medical College, Yan'an University, Yan'an, Shaanxi 716000, P.R. China.
Guimei LiuDepartment of Clinical Laboratory, The Affiliated Hospital of Yan'an University, Yan'an, Shaanxi 716000, P.R. China.
Xiaobin LiuDepartment of Medical Immunology, Yan'an Medical College, Yan'an University, Yan'an, Shaanxi 716000, P.R. China.
Yiyuan YangDepartment of Medical Immunology, Yan'an Medical College, Yan'an University, Yan'an, Shaanxi 716000, P.R. China.
Yufu ZhangDepartment of Hepatobiliary and Pancreatic Surgery, The Affiliated Hospital of Yan'an University, Yan'an, Shaanxi 716000, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gemcitabine (GEM) is the first‑line chemotherapy drug for pancreatic cancer, but its efficacy is often limited by inherent drug resistance. Saikosaponin D (SSD), a bioactive triterpenoid saponin derived from the

Indexed as

DeoxycytidineDrug Resistance, NeoplasmOleanolic AcidPancreatic NeoplasmsSaponinsAntineoplastic Combined Chemotherapy ProtocolsApoptosisAutophagyCell Line, TumorCell ProliferationDrug SynergismGemcitabineHumansProto-Oncogene Proteins c-aktSignal TransductionTOR Serine-Threonine KinasesDeoxycytidineGemcitabineMTOR protein, humanOleanolic AcidProto-Oncogene Proteins c-aktsaikosaponin DSaponinsTOR Serine-Threonine KinasesAKT/mTOR signaling pathwayapoptosisautophagygemcitabinepancreatic cancerSaikosaponin D

Identifiers

PMID41347830
PMCPMC12709144

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.